EarningsQ4 2026 Earnings Report
MX:CSLN Q4 2026 EPS Results
Actual EPS$38.77
Consensus EPS$40.40
Beat/MissMissed by -$1.63
One Year Ago EPS$40.32
MX:CSLN Q4 2026 Revenue Results
Actual Revenue$128.83B
Expected Revenue$121.93B
Beat/MissBeat by +$6.90B
YoY Revenue Growth-4.40%
Earnings Announcement Details
QuarterQ4 2026
Date08/17/2026
TimeAfter Close
Conference CallMonday, August 17, 2026
MX:CSLN Upcoming Earnings
CSL's next earnings date is estimated for February 9, 2027, based on past reporting schedules.
Q4 2026 Earnings Call Audio
MX:CSLN Q4 2026 Earnings Call
0:00 / 0:00
Q4 2026 Earnings Slide Deck
Q4 2026 Earnings Call Summary
Earnings Call Sentiment|Negative
The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.Company Guidance
Solid cash generation and shareholder returns
Operating cash flow of $3.5B supported completion of an AUD 1.0B buyback in FY'26, maintenance of the full-year dividend at $2.92 per share (U.S. dollars), and an authorized further buyback of ~AUD 1.1B for FY'27.
Transformation program ahead of plan
Transformation delivered $176M of savings in FY'26 (ahead of $100M target). Management expects an incremental ~$220M of savings in FY'27 (annualized ~ $400M) rising to up to ~$550M in FY'28, with disciplined reinvestment of a portion of savings into growth initiatives.
Improving Ig commercial momentum (Behring)
CSL Behring Ig revenue broadly flat for FY'26, but second-half Ig revenue grew 7% year-on-year and 4% on the preceding half. Management guides Ig to grow in line with the market at mid- to high-single-digit in FY'27 and expects Behring to deliver mid-single-digit revenue growth.
Strong performance from new and specialty products
ANDEMBRY launch exceeded expectations and is available in 19 markets; HEMGENIX grew 25% in FY'26; FILSPARI and Veltassa showing early uptake in nephrology launch markets.
Seqirus continued market differentiation and share gains
Seqirus was the only global influenza participant to grow seasonal influenza revenue YoY: seasonal influenza +4%, adjuvanted portfolio +5%, cell culture +5%. Operational separation completed cost‑neutrally; AUJEMFLU approved in the U.K. and received positive CHMP recommendation.
Plasma network and operational improvements
CSL maintained plasma volumes while closing underperforming centers, progressed yield and productivity initiatives (including phased Haemonetics platform adoption), commenced Kankakee Ig facility construction, and reduced R&D and G&A expenses by 13% each.
MX:CSLN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed